Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is a Angiotensin II receptor blocker presented as a tablet for oral use. It lowers elevated blood pressure and protects target organs in adult patients with hypertension. GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker that acts on the renin‑angiotensin system to control blood pressure and related complications. - Hypertension: reduces systolic and diastolic blood pressure in adults with high blood pressure. - Diabetic nephropathy: slows the progression of renal impairment in patients with type 2 diabetes. - Cardiovascular risk reduction: lowers the risk of stroke and myocardial events in hypertensive patients with left ventricular hypertrophy.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or lacking energy. - Nasal congestion: blocked or runny nose. - Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of the face, lips, tongue, or throat. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Severe hypotension: markedly low blood pressure causing fainting.

Patients should be aware of specific safety considerations before starting therapy. - Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte checks: monitor potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy warning: contraindicated in pregnancy (Category D) due to fetal toxicity. - Concomitant NSAIDs: avoid or use with caution as they may impair renal function. - Volume depletion: ensure adequate hydration before initiating treatment. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Irbesartan may interact with several medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients can increase renal risk. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use raises risk of hypotension and renal impairment.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive effect and affect kidneys. - Lithium: may increase lithium levels, necessitating serum monitoring. - CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations.